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Repeated Mechanical Endovascular
Thrombectomy for Recurrent Large Vessel
Occlusion
A Multicenter Experience
Ghada A. Mohamed , MD; Hassan Aboul Nour , MD; Raul G. Nogueira , MD; Mahmoud H. Mohammaden, MD;
Diogo C. Haussen , MD; Alhamza R. Al-Bayati , MD; Thanh N. Nguyen , MD; Mohamad Abdalkader , MD;
Artem Kaliaev, MD; Alice Ma , MD; Johanna Fifi , MD; Jacob Morey , MD; Dileep R. Yavagal , MD; Vasu Saini , MD;
Santiago Ortega-Gutierrez , MD; Mudassir Farooqui , MD; Cynthia B. Zevallos , MD; Darko Quispe-Orozco , MD;
Lonni Schultz, PhD; Maximilian Kole, MD; Daniel Miller, MD; Stephan A. Mayer , MD; Horia Marin , MD; Alex Bou Chebl , MD
BACKGROUND AND PURPOSE: Mechanical thrombectomy (MT) is now the standard of care for large vessel occlusion (LVO)
stroke. However, little is known about the frequency and outcomes of repeat MT (rMT) for patients with recurrent LVO.
METHODS: This is a retrospective multicenter cohort of patients who underwent rMT at 6 tertiary institutions in the United
States between March 2016 and March 2020. Procedural, imaging, and outcome data were evaluated. Outcome at discharge
was evaluated using the modified Rankin Scale.
RESULTS: Of 3059 patients treated with MT during the study period, 56 (1.8%) underwent at least 1 rMT. Fifty-four (96%)
patients were analyzed; median age was 64 years. The median time interval between index MT and rMT was 2 days; 35 of
54 patients (65%) experienced recurrent LVO during the index hospitalization. The mechanism of stroke was cardioembolism
in 30 patients (56%), intracranial atherosclerosis in 4 patients (7%), extracranial atherosclerosis in 2 patients (4%), and
other causes in 18 patients (33%). A final TICI recanalization score of 2b or 3 was achieved in all 54 patients during index
MT (100%) and in 51 of 54 patients (94%) during rMT. Thirty-two of 54 patients (59%) experienced recurrent LVO of a
previously treated artery, mostly the pretreated left MCA (23 patients, 73%). Fifty of the 54 patients (93%) had a documented
discharge modified Rankin Scale after rMT: 15 (30%) had minimal or no disability (modified Rankin Scale score ≤2), 25
(50%) had moderate to severe disability (modified Rankin Scale score 3–5), and 10 (20%) died.
CONCLUSIONS: Almost 2% of patients treated with MT experience recurrent LVO, usually of a previously treated artery during
the same hospitalization. Repeat MT seems to be safe and effective for attaining vessel recanalization, and good outcome
can be expected in 30% of patients.
Key Words: arteries ◼ atherosclerosis ◼ ischemic stroke ◼ standard of care ◼ thrombectomy

I

n 2015, mechanical thrombectomy (MT) became the
standard of care for the treatment of acute ischemic
stroke due to large vessel occlusion (LVO) within 6
hours.1,2 In 2018, the treatment window was expanded
up to 24 hours from acute ischemic stroke symptom

onset.3,4 On average, the 5-year risk of acute ischemic
stroke recurrence is 24% for women and 42% for men,
with most of the risk within the first 2 weeks after the
index event.5,6 With estimates of 65 000 to 90 000
patients meeting MT criteria annually in the United
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Nonstandard Abbreviations and Acronyms
iMT
index mechanical thrombectomy
LVO
large vessel occlusion
mRS
modified Rankin Scale
MT
mechanical thrombectomy
NIHSS	National Institutes of Health Stroke
Scale
rLVO
recurrent LVO
rMT
repeat mechanical thrombectomy

States, the number of patients who may experience a
recurrent LVO (rLVO) requiring repeat MT (rMT) may
be substantial.7
The literature on the safety and outcomes of rMT,
especially in the same vascular territory, is limited.
Fandler et al8 showed that successful rMT could be
achieved in a patient with recurrent early reocclusion
of the same artery within 24 hours. Bouslama et al9
reported on 14 patients with rMT and showed that there
were no statistically significant differences in demographics, stroke severity, time from last known normal to groin puncture, reperfusion rates, hemorrhagic
complications, good functional outcomes, or mortality
between patients who underwent rMT and those who
were treated with a single thrombectomy.
The cause of rLVO is also not well described. Up to
20% of LVO is caused by atherosclerosis because of
plaque rupture leading to vessel thrombosis or arteryto-artery embolism.10 A population-based study showed
that atherosclerotic large vessel disease carried the highest risk of stroke recurrence.11 This risk correlates with
plaque echogenicity.12Additionally, atrial fibrillation, which
is the primary cause of cardioembolic stroke, is associated with increased risk for early stroke recurrence.12
Understanding the frequency, timing, causes, and
angiographic and clinical outcomes associated with rMT
may help develop preventive medical strategies and optimize the endovascular approach (ie, use of stent-retriever
versus suction thrombectomy versus angioplasty/stenting). In this study, we aimed to describe our cumulative
experience with consecutive cases of rMT for rLVO at 6
US medical centers over a period of 4 years.

METHODS
Study Design
Repeated Mechanical Endovascular Thrombectomy for
Recurrent Large Vessel Occlusion is a retrospective multicenter
cohort study that identified patients who underwent rMT at 6
United States comprehensive stroke centers between March
2016 and March 2020. All data were prospectively collected
in endovascular databases maintained by the investigators. The
2   June 2021
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institutional review boards of all 6 institutions approved this
study, which included a data-sharing agreement. The data that
support the findings of this study are available from the corresponding author upon reasonable request.

Clinical Variables
Patients who received an index MT (iMT) in the 6 participating centers were analyzed, and cases in which rMT was
performed were identified. All patients received baseline
noncontrast computed tomography (NCCT), CT angiography upon presentation, and 24 hours postprocedural NCCT
or earlier if clinically indicated. Stroke work-up included
in-hospital cardiac rhythm monitoring, and transthoracic or
transesophageal echocardiography in all cases. Antiplatelet
agents were started either immediately or within 24 hours
after thrombectomy unless hemorrhagic infarction was present. Anticoagulation when indicated for atrial fibrillation was
started between 3 and 14 days after thrombectomy unless
hemorrhage was present.
Demographics, risk factors, clinical, imaging, procedural
devices used, number of passes, final TICI score, post-iMT
antithrombotic therapy, and outcome at discharge were
collected. We defined early reocclusion as occurring during the index hospitalization. Stroke severity was measured with the National Institutes of Health Stroke Scale
(NIHSS).13 Stroke cause was classified based on the TOAST
criteria.14 Successful reperfusion was defined as a modified Thrombolysis in Cerebral Infarction score of 2b or 3.15
Postprocedural hemorrhagic complications were defined
using the European Cooperative Acute Stroke Study criteria.16 Neurological outcomes were measured with the modified Rankin Scale (mRS) at the time of hospital discharge.
Favorable outcome was defined as mRS score <2 and unfavorable as mRS score 3 to 5, with mortality mRS score 6
counted separately.
Treatment plans were based on each hospital’s protocol,
including various interventional approaches, for example, aspiration catheters, stent retriever devices, stents, angioplasty balloons, or combinations thereof.

Statistical Analysis
We used proportions, median, and interquartile ranges for
descriptive statistics. For comparisons between iMT and rMT,
McNemar tests were used for the dichotomized variables,
Bowker test for symmetry for the categorical variables, and
Wilcoxon signed-rank tests for the continuous variables.
For comparisons between patients with reocclusion during hospitalization and reocclusion after discharge, Fisher
exact test was used for dichotomized and categorical variables and Wilcoxon 2-sample tests for continuous variables.
Significance was set at <0.05, and 2-sided P values were
reported. Statistical analysis was performed using R Software
(version 3.6.1) and SAS (version 9.4).

RESULTS
Of 3059 patients who underwent MT at 6 comprehensive
stroke centers between March 2018 and March 2020,
56 patients (1.8%) underwent rMT. Fifty-four patients
Stroke. 2021;52:00–00. DOI: 10.1161/STROKEAHA.120.033393
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Table 1. Demographics of 54 Patients Treated With Repeat
Mechanical Thrombectomy
Characteristic

N=54

Age, y

64 (54–72)

Female

27 (50)

LVO recurrence after the index event
   One recurrence

50 (93)

Two recurrences

3 (6)

Three recurrences

1 (12)

Time interval in days between index MT and first rMT, d

2 (0.8–17.8)

Reocclusion during index hospitalization

35 (65)

Reocclusion of same vascular territory

32 (59)

Data are N (%) or median (IQR). LVO indicates large vessel occlusion; MT,
mechanical thrombectomy; and rMT, repeat MT.

Stroke. 2021;52:00–00. DOI: 10.1161/STROKEAHA.120.033393

fixed focal stenosis of the repeatedly treated left MCA
that eventually required angioplasty.
Median NIHSS at presentation was 14 (range, 9–21)
for iLVO and 16 (range, 10–24) for rLVO (P=0.96,
Table 2). However, post MT NIHSS scores were worse
after rMT compared with iMT (median 12 versus 7,
P=0.008, Table 2) and worse when rMT was performed
during the same hospitalization compared with those
with reocclusion after discharge (median 7 versus 5,
P=0.028, Table 3).
Successful revascularization was achieved with 1
pass in 32 of 54 patients (59%) during iMT and in 26
(48%) during rMT. A final recanalization score of modified Thrombolysis in Cerebral Infarction 2b or 3 was
achieved in all 54 patients during their iMT (100%) and
in 51 of 54 patients (94%) during rMT (Table 2).
Postprocedural intracerebral hemorrhage occurred in
4 of 54 patients (7%) after iMT, 2 of which were symptomatic. After rMT, 7 of 54 patients (13%) had postprocedure intracerebral hemorrhage, 4 of which (7%) were
symptomatic, of 2 of which were fatal (Table 2).
Fifty of 54 patients (93%) had a documented discharge mRS after rMT: 15 (30%) had minimal or no
disability (mRS score ≤2), 25 (50%) had moderate to
severe disability (mRS score 3–5), and 10 (20%) died
(Table 2).

DISCUSSION
Large vessel occlusion (LVO) accounts for 30% of ischemic stroke presentations.17 The 5-year risk of ischemic
stroke recurrence due to all stroke etiologies combined
is about 30%.18 To our knowledge, our study represents
the largest cohort of patients receiving rMT for rLVO
in North America to date. In this cohort, rLVO requiring
MT was infrequent, occurring after 1.8% of all MT procedures. Similar and slightly lower rates (0.4%–1.5%)
have been previously reported in smaller series.9,19–22
These infrequent treatment rates likely represent an
underestimate of the actual number of rLVO due to:
exclusion of patients with rLVO with severe disability,
patients presenting with rLVO to different hospitals, and
missed rLVO during hospitalization in patients with a
subtle worsening of the original NIHSS.
In our cohort, the majority of rLVO occurred early,
within a median time to reocclusion of 2 days. Thirty-five
patients, 65% developed rLVO during the index hospitalization after successful iMT. A study on very early
reocclusion within 48 hours showed that cardio-embolism and atherosclerotic large vessel disease were the
first and second most common etiologies associated
with reocclusion after successful revascularization.23
We found similar results, with cardioembolism (51%)
and large vessel atherosclerosis (17%) being the most
likely stroke mechanisms associated with early rLVO.
Other causes that may contribute to early reocclusion
June 2021   3
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were analyzed, with 2 patients excluded because of
incomplete iMT clinical and procedural data.
Fifty patients (93%) had 1 rMT, 3 (6%) underwent 2
rMT procedures, and 1 (2%) had rMT performed 3 times.
Median age was 64 (interquartile range, 54–72) years,
and 50% were females (Table 1).
Median time interval between the index LVO (iLVO)
and rLVO was 2 days (range, 0.8–17.8 days); in 35
patients (65%), rMT was performed during the index
hospitalization (Table 2). There was no statistically significant difference in stroke cause, ASPECTS (Alberta
Stroke Program Early CT Score), number of passes during MT, or final modified Thrombolysis in Cerebral Infarction score between those who had reocclusion during
hospitalization or reocclusion after discharge (Table 3).
At the time of rMT, 13 patients (24%) were not
started on any antithrombotic therapy, 27 patients (50%)
received antiplatelet therapy, and 14 patients (26%)
were on full anticoagulation (Table 1). Patients with rLVO
during hospitalization were less commonly receiving secondary stroke prevention compared with patients with
rLVO after discharge (34% versus 5%, P=0.022). Both
groups had similar discharge mRS (Table 3).
In 30 patients (56%), rLVO occurred in patients with a
cardioembolic cause of stroke, with the majority of these
(23 of 35, 77%) due to atrial fibrillation. Six patients
(11%) had rLVO due to atherosclerotic in situ thrombosis: intracranial atherosclerotic disease in 4 (7%), and
extracranial atherosclerosis in 2 (4%). In the remaining
18 patients (33%) rLVO was secondary to other causes
(eg, vasculitis) or was cryptogenic (Table 2).
Thirty-two of 54 patients (59%) had rLVO of the same
vessel treated during iMT. The most common stroke
cause in these patients was cardiac embolism (13/32,
41%), and the left MCA was the most commonly affected
vessel in these cases (23/32, 72%) (Table 2). Of the 4
patients who underwent 2 or more rMT procedures, 3
had atrial fibrillation and 1 patient had intracranial stent
thrombosis. The single patient who underwent 3 repeat
thrombectomies had atrial fibrillation and developed a
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Table 2. Procedural Characteristics Comparing Index Mechanical Thrombectomy and the First Recurrent Thrombectomy
Characteristic

Index MT

First rMT

P value

Presenting NIHSS

14 (9–21)

16 (10–24)

0.16*

Table 3. Comparison Between Reocclusion During Index
Hospitalization Versus After Discharge

ASPECTS

9 (8–10)

9 (8–10)

0.96*

Characteristic

Reocclusion
during index
hospitalization, N=35

Postprocedural NIHSS

7 (3–12)

12 (5–21)

0.008*

Age, y

62 (53–68)

67 (60.5–80)

0.07*

0.45†

ASPECTS

9 (8–10)

9 (7.5–9)

0.19*

Postprocedural NIHSS

7 (4–14)

5 (1–7)

0.028*

1 (0–2)

Arterial territory
MCA

40 (74)

34 (63)

Basilar artery

6 (11)

9 (17)

Time interval, d

ICA

7 (13)

10 (17)

Number of passes

PCA

1 (2)

1 (2)

Endovascular approach

0.018†

1 pass

18 (51)

>1 pass

17 (49)

Reocclusion after
discharge,
N=19

P value

75 (11–390)

<0.001*

14 (74)

0.15†

5 (26)

Stent retriever

43

41

Index stroke cause

Aspiration

13

20

Cardioembolic

18 (51)

2 (11)

Intracranial angioplasty

1

3

Atherosclerotic

6 (17)

5 (26)

Intracranial stenting

0

3

Other causes

11 (31)

Extracranial angioplasty

0

0

Extracranial stenting

0

2

1 pass

32 (59)

26 (48)

>1 pass

22 (41)

28 (52)

Number of passes

0.32‡

mTICI score
2b-3
1–2a
Hemorrhage
Symptomatic§
Fatal

0.25‡
54 (100)
0 (0)

3 (6)

4 (7)

7 (13)

2 (4)
0 (0)

No

28 (80)

17 (49)

2 (4)

6 (17)

4 (7)

4 (7)

 Extracranial atherosclerotic
disease

4 (7)

4 (7)
18 (33)

  Cryptogenic

11 (20)

11 (20)

  Vasculitis

1 (2)

1 (2)

  Dissection

0 (0)

1 (2)

  Hypercoagulable state

4 (7)

4 (7)

  Stent thrombosis

0 (0)

1 (2)

Follow-up mRS

N=45

N=50

Favorable (mRS score ≤2)

17 (38)

15 (30)

Unfavorable (mRS score 3–5)

28 (62)

25 (50)
10 (20)

Data are N (%) or median (IQR). ACA indicates anterior cerebral artery;
ASPECTS, Alberta Stroke Program Early CT Score; ESUS, embolic stroke of
undetermined source; ICA, internal carotid artery; ICH, intracerebral hemorrhage;
IQR, interquartile range; MCA, middle cerebral artery; mRS, modified Rankin Scale;
MT, mechanical thrombectomy; mTICI, modified Thrombolysis in Cerebral Infarction; NIHSS, National Institutes of Health Stroke Scale; PCA, posterior cerebral
artery; and RT, recurrent thrombectomy.
*P value from signed-rank test.
†P value from Bowker test for symmetry.
‡P value from McNemar test.
§Symptomatic hemorrhage corresponds to PH2 (hematoma occupying 30% or
more of the infarcted tissue, with obvious mass effect) according to the Heidelberg bleeding classification.

0.08†

0 (0)

0.043†

19 (100)

0.02†

10 (53)

Anticoagulation
Follow-up mRS

0.78

8 (42)

1 (5)

Antiplatelets

 Intracranial atherosclerotic
disease

4   June 2021

7 (20)

4 (7)

30 (56)

Death (mRS score 6)

Yes

12 (34)

0.18‡

0.75†

16 (30)

Need for stenting, angioplasty, or both

None

30 (56)

Other causes

24 (69)

Medications used following
index MER

51 (94)

Stroke cause
Cardioembolic

Reocclusion of same vascular
territory

12 (63)

8 (42)

N=32

N=18

Favorable mRS (≤2)

10 (31)

5 (28)

Unfavorable mRS (3–5)

18 (56)

Death

4 (13)

0.28*

7 (39)

Follow-up mRS, median (IQR)

6 (33)

N=32

N=18

4 (2–4.5)

4 (1–6)

0.39*

Data are N (%) or median (IQR). ASPECTS indicates Alberta Stroke Program Early CT Score; IQR, interquartile range; mRS, modified Rankin Scale; and
NIHSS, National Institutes of Health Stroke Scale.
*P value from Wilcoxon 22-sample test.
†P value from Fisher exact test.

are procedure-related complications like dissection and
stent thrombosis.22 These complications were infrequent in our cohort.
The primary cause for rLVO in our cohort was cardioembolic source, about 56% of the 54 patients, with
majority due to atrial fibrillation (77%). This is consistent
with prior studies showing that cardioembolic source is
the cause of up to 40% of acute ischemic strokes,24 and
43% to 67% of rLVO.19–22
Thirty-two of the 54 patients in our cohort (59%)
had reocclusion of the previously treated artery. Recurrent LVO of the same vessel might intuitively seem more
likely to occur in patients with intracranial atherosclerotic
disease or extracranial atherosclerosis. On the contrary,
Stroke. 2021;52:00–00. DOI: 10.1161/STROKEAHA.120.033393
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patients with rLVO were not on antiplatelet or anticoagulant therapy before the reocclusion. Patients with early
rLVO during hospitalization were less frequently started
on antithrombotic therapy after iMER than the late rLVO
group (34% versus 5%, P=0.022). These data suggest
that earlier initiation of antithrombotic therapy may prevent rLVO, but this needs to be balanced against the
risk of intracerebral hemorrhage related to early initiation of antithrombotic therapy. More prospective data are
needed to study the role of early versus late initiation of
antithrombotic therapy after MT.
First pass revascularization was achieved in 32 of the
54 rLVO patients during iMT (59%) and in 26 of the 54
during rMT (48%). All 54 patients with rLVO had initial
successful reperfusion on iMT (modified Thrombolysis
in Cerebral Infarction 2b/3), and rMT led to successful
recanalization in 51 patients (94%), mostly with the combination of stent retrieval and aspiration. Postprocedural
neurological deficits were worse after the rMT compared
with iMT (median NIHSS 12 versus 7, P=0.008). This
finding is expected since the patients undergoing rMT
already had deficit from the index stroke. Reassuringly,
the rate of intracerebral hemorrhage was not substantially different with rMT compared with the iMT and
accepted rates seen in trials of MT.33
Data on the safety and long-term outcomes of MT in
the setting of high premorbid mRS are limited. The AHA/
ASA guidelines state that patients with premorbid mRS
score >1 have uncertain benefits and further randomized
controlled trials are necessary.34 Seker et al35 showed
that patients with premorbid mRS score 3 to 4 could
return to their premorbid mRS after MT, which can justify
MT for those patients. These considerations are relevant
to the consideration of performing rMT in patients with
rLVO. Thirty-five of the 54 patients had rMT during the
index hospitalization due to early reocclusion. Although
not strictly within the guidelines, treatment with rMT for
these patients may have been reasonable because of the
short period since the initial stroke, being already hospitalized and could potentially be treated ultra-early. At
discharge time, 30% had minimal or no disability (mRS
score ≤2) after rMT, 50% had moderate to severe disability (mRS score 3–5). Based on this study’s results,
these patients’ outcomes seem to be acceptable with
a favorable discharge mRS of 30%, which would be
expected to rise at 3 months. Furthermore, patients with
rLVO may be sicker and may have a worse functional
baseline from their previous stroke, which may negatively
affect functional recovery after rMT.
Again, we have no doubt that judicious patient selection played a role in selecting patients with rLVO for
rMT, contributing to some of the good outcomes that
we observed.
Overall mortality in our cohort was 20%, comparable
to other recurrent large vessel occlusion studies (18%–
20%).9,20–23 However, this was slightly higher than the
June 2021   5
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in our series, cardioembolism was the most common
stroke mechanism associated with reocclusion of the
pretreated artery (41% of the 32 patients), and the left
MCA was more commonly affected than the right. This
finding may be explained by hemodynamics, laminar flow
patterns, vascular diameter, and aortic arch morphology,
all of which play a role in cardioembolic stroke’s laterality.25,26 Elsaid et al26 studied the relationship between cardioembolic stroke and aortic arch morphology and found
that cardioembolic strokes tend to occur more frequently
in the anterior circulation, left MCA territory. Another
possible explanation is that patients with an underlying
stenosis, especially if severe, may have had definitive
revascularization (angioplasty or stenting) during the iMT
or shortly thereafter or even early carotid endarterectomy, creating a bias in our dataset.
Mosimann et al27 showed in their study of predictors
of early reocclusion after MT that the majority of early
reocclusions occurred in patients with residual embolic
fragments that were not recognized on the final control
run, misinterpreted as focal spasm, or were suboptimally
imaged due to overlapping branches.
Other possibility for rLVO in the same location is local
vascular endothelial injury caused by the iMT maneuver itself. Previous studies have shown that endothelial
injury from the MT can result in a predilection to acute insitu thrombosis and reocclusion.28 In preclinical studies,
thrombectomy-induced vascular wall damage was found
to manifest as endothelial injury, disruption of the internal
elastic lamina, and focal edema located in the intimal and
medial layers of the vessel.29 Additionally, more than half
of clots retrieved from patients treated with MT contained
endothelial cells, suggesting intimal layer damage due to
direct mechanical injury from MT.29 Anecdotaly, one of
our patients with cardioembolic stroke with atrial fibrillation developed fixed focal stenosis after the third rMT
in the same vascular territory that required angioplasty.
The optimal timing for initiation of antithrombotic
therapy in patients presenting with acute cardioembolic
LVO is controversial. In the current guidelines, no available prospective data address the appropriate timing for
initiation of anticoagulation or antiplatelet agent after MT,
especially when intravenous thrombolysis is given. The
dilemma is that there is an increased risk of early recurrent stroke for patients with atrial fibrillation, intracardiac thrombi, unstable plaques, or extensive intracranial
stenosis. However, there is also a known increased risk
of hemorrhagic transformation of the infarcted tissue.30
A protocol has been proposed to address the timing of
anticoagulation timeline in patients with a cardioembolic
source based on the index stroke volume.31 Retrospective studies of early reocclusion after successful MT
have found a relationship between atherosclerotic disease, preprocedural platelet counts, and the rate of rLVO,
concluding that pretreatment antiplatelet therapy might
reduce the rate of recurrence.32 In our cohort, 24% of
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mortality figures (10%–15%) reported in the randomized
thrombectomy trials.36
Our study has limitations, mainly its retrospective
nature. Also, the low rate of rLVO requiring rMT hampered our ability to do multivariable regression analysis.
We have missing outcomes data for 4 patients treated
with MT. However, our cohort’s rate of favorable functional outcomes is comparable to other rMT studies and
is only slightly less than the landmark randomized trials.
Our data clearly underestimate the absolute rate of rLVO
since we only captured patients who qualified for rMT.
Since we only had outcome data at hospital discharge,
our data may underestimate the good neurological outcome rate with rMT, which is better assessed at 90 to
180 days. Finally, the study centers are comprehensive
stroke centers in the United States; practices and patient
selection for rMT may be different in other health care
systems worldwide.

CONCLUSIONS
To our knowledge, this is the largest multicenter study
in North America of rLVO requiring rMT. Almost 2%
of patients treated with MT experience rLVO, usually
of a previously treated artery during the same hospitalization. Repeat MT seems to be safe and effective
for attaining vessel recanalization, and good outcome
can be expected in 30% of patients. Inadequate anticoagulation or antiplatelet therapy and a cardioembolic source may be risk factors for early rLVO. Further
research is needed to better understand the true rate
or rLVO after MT, and to identify optimal treatment
strategies to minimize this risk.
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